S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)

Verona Pharma (VRNA) Stock Forecast, Price & News

$3.91
+0.19 (+5.11%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$3.73
$3.93
50-Day Range
$3.55
$5.31
52-Week Range
$3.41
$7.87
Volume
33,175 shs
Average Volume
81,600 shs
Market Capitalization
$236.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.67
30 days | 90 days | 365 days | Advanced Chart
Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

Verona Pharma logo

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRNA
Fax
N/A
Employees
24
Year Founded
N/A

Sales & Book Value

Annual Sales
$40 million
Book Value
$2.09 per share

Profitability

Net Income
$-55.57 million
Pretax Margin
-147.83%

Debt

Price-To-Earnings

Miscellaneous

Free Float
58,014,000
Market Cap
$236.04 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/03/2022
Today
5/20/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

372nd out of 1,420 stocks

Pharmaceutical Preparations Industry

150th out of 679 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -













Verona Pharma (NASDAQ:VRNA) Frequently Asked Questions

Is Verona Pharma a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Verona Pharma stock.
View analyst ratings for Verona Pharma
or view top-rated stocks.

Are investors shorting Verona Pharma?

Verona Pharma saw a decline in short interest in April. As of April 30th, there was short interest totaling 32,300 shares, a decline of 46.5% from the April 15th total of 60,400 shares. Based on an average trading volume of 72,200 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.1% of the company's shares are short sold.
View Verona Pharma's Short Interest
.

When is Verona Pharma's next earnings date?

Verona Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Verona Pharma
.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) issued its earnings results on Thursday, March, 3rd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10.
View Verona Pharma's earnings history
.

What price target have analysts set for VRNA?

2 analysts have issued 1-year price objectives for Verona Pharma's shares. Their forecasts range from $17.00 to $25.00. On average, they expect Verona Pharma's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 437.1% from the stock's current price.
View analysts' price targets for Verona Pharma
or view top-rated stocks among Wall Street analysts.

Who are Verona Pharma's key executives?
Verona Pharma's management team includes the following people:
  • Dr. David S. Zaccardelli, Pres, CEO & Exec. Director (Age 57, Pay $627.27k) (LinkedIn Profile)
  • Mr. Mark W. Hahn, Chief Financial Officer (Age 59, Pay $639.08k) (LinkedIn Profile)
  • Dr. Kathleen A. Rickard, Chief Medical Officer (Age 64, Pay $562.38k)
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 55)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 60)
  • Dr. Tara Rheault M.P.H., Ph.D., Sr. VP of R&D (Age 45)
  • Ms. Nina Church, Exec. Director of Global Clinical Devel.
  • Mr. Christopher Martin, Sr. VP of Commercial
  • Ms. Caroline Diaz, Sr. VP of Regulatory Affairs
What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (6.26%), Citigroup Inc. (0.61%), GSA Capital Partners LLP (0.02%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Verona Pharma stock include Anders Ullman, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn and Patrick John Finn.
View institutional ownership trends for Verona Pharma
.

Which institutional investors are selling Verona Pharma stock?

VRNA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, and Simplex Trading LLC. Company insiders that have sold Verona Pharma company stock in the last year include David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, and Mark W Hahn.
View insider buying and selling activity for Verona Pharma
or view top insider-selling stocks.

Which institutional investors are buying Verona Pharma stock?

VRNA stock was bought by a variety of institutional investors in the last quarter, including Citigroup Inc., and GSA Capital Partners LLP.
View insider buying and selling activity for Verona Pharma
or or view top insider-buying stocks.

How do I buy shares of Verona Pharma?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $3.91.

How much money does Verona Pharma make?

Verona Pharma has a market capitalization of $236.04 million and generates $40 million in revenue each year. The company earns $-55.57 million in net income (profit) each year or ($1.190010) on an earnings per share basis.

How many employees does Verona Pharma have?

Verona Pharma employs 24 workers across the globe.

What is Verona Pharma's official website?

The official website for Verona Pharma is www.veronapharma.com.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 011-44-0-2032834200 or via email at [email protected].

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.